Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients

British Journal of Cancer

Volumn 102, Issue 4, 2010, Pages 731-737

  Taubert, H ^a   Wurl P ^b   Greither, T ^a   Kappler, M ^a   Bache, M ^a   Lautenschlager C ^a   Fussel S ^c   Meye, A ^d   Eckert, A W ^a   Holzhausen, H J ^a   Magdolen, V ^e   Kotzsch, M ^c  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Medizinisches Labor Ostsachsen   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Prognosis; Sarcoma patients; Urokinase plasminogen activator system

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE EXTRACT; UROKINASE; UROKINASE RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSARCOMA; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; NEUROFIBROSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIAGNOSTIC TECHNIQUES AND PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SARCOMA; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 76949087024     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605520     Document Type: Article

References (35)

1. Abendstein B, Daxenbichler G, Windbichler G, Zeimet AG, Geurts A, Sweep F, Marth C (2000) Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. Anticancer Res 20: 569-572
2. Brünner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O, Stephens RW (1999) The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 107: 160-167 (Pubitemid 29133536)
3. Choong PF, Fernö M, Akerman M, Willén H, Langström E, Gustafson P, Alvegard T, Rydholm A (1996) Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer 69: 268-272
4. Clark JC, Dass CR, Choong PF (2008) A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 134: 281-297
5. Dass CR, Choong PF (2008) uPAR mediates anticancer activity of PEDF. Cancer Biol Ther 7: 1262-1270
6. Dass CR, Nadesapillai AP, Robin D, Howard ML, Fisher JL, Zhou H, Choong PF. (2005) Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin Exp Metastasis 22: 643-652
7. Duffy MJ (2004) The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10: 39-49
8. Duffy MJ, Duggan C (2004) The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 37: 541-548
9. Duffy MJ, McGowan PM, Gallagher WM (2008) Cancer invasion and metastasis: changing views. J Pathol 214: 283-293
10. Fisher JL, Mackie PS, Howard ML, Zhou H, Choong PF (2001) The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin Cancer Res 7: 1654-1660
11. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ (2000) Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 60: 5839-5847
12. Herszényi L, Farinati F, Cardin R, István G, Molnár LD, Hritz I, De Paoli M, Plebani M, Tulassay Z (2008) Tumour marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 8: 194
13. Holst-Hansen C, Hamers MJ, Johannessen BE, Brünner N, Stephens RW (1999) Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. Br J Cancer 81: 203-211
14. Iwadate Y, Hayama M, Adachi A, Matsutani T, Nagai Y, Hiwasa T, Saeki N (2008) High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res 28: 415-418
15. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H (1994) Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54: 2527-2530
16. Luther T, Flössel C, Albrecht S, Kotzsch M, Müller M (1996) Tissue factor expression in normal and abnormal mammary gland. Nat Med 2: 491-492
17. Madsen MA, Deryugina EI, Niessen S, Cravatt BF, Quigley JP (2006) Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation. J Biol Chem 281: 15997-16005
18. McMahon B, Kwaan HC (2007-2008) The plasminigen activator system and cancer. Pathophysiol Haemost Thromb 36: 184-194
19. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, Khan A, Morrison L, Herlyn D, Terstappen LW, Lane N, Wang J, Uhr J (2006) uPAR and HER-2 gene status in individual breast cancer cells from blood and tissue. PNAS 46: 17361-17365
20. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999) Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39: 123-129
21. Mondino A, Blasi F (2004) uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 25: 450-455
22. Mustjoki S, Sidenius N, Sier CF, Blasi F, Elonen E, Alitalo R, Vaheri A (2000) Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 60: 7126-7132
23. Pillay V, Dass CR, Choong PF (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 25: 33-39
24. Ragno P (2006) The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol Life Sci 63: 1028-1037
25. Rha SY, Yang WI, Gong SJ, Kim JJ, Yoo NC, Roh JK, Min JS, Lee KS, Kim BS, Chung HC (2000) Correlation of tissue and blood plasminogen activation system in breast cancer. Cancer Lett 150: 137-145
26. Rigolin GM, Tieghi A, Ciccone M, Bragotti LZ, Cavazzini F, Della Porta M, Castagnari B, Carroccia R, Guerra G, Cuneo A, Castoldi G (2003) Soluble urokinase-type plasminogen activator receptor (suPAR) as an indepen-dent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. Br J Haematol 120: 953-959
27. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Høyer-Hansen G, Smith K, Brünner N, Harris AL (2002) Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 8: 1132-1141
28. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM (2007) Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25: 349-355
29. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F (1998) The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58: 1843-1849
30. Silberman S, Janulis M, Schultz RM (1997) Characterization of downstream Ras signals that induce alternative protease-dependent invasive pheno-types. J Biol Chem 272: 5927-5935
31. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N. (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91: 869-874
32. Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J (1998) Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Eur J Cancer 34: 1193-1197
33. Tang CH, Wei Y (2008) The urokinase receptor and integrins in cancer progression. Cell Mol Life Sci 65: 1916-1932
34. Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J (2008) Modification of kidney barrier function by the urokinase receptor. Nat Med 14: 55-63
35. Würl P, Kappler M, Meye A, Bartel F, Köhler T, Lautenschläger C, Bache M, Schmidt H, Taubert H (2002) Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet 359: 943-945